| 摘要 |
Celecoxib, a COX-2 specific non-steroidal anti-inflammatory agent, is provid ed in combination with DFMO for the prevention and/or treatment of cancers. Provided with the present invention are pharmaceutically acceptable compositions that include a non-steroidal anti-inflammatory agent, celecoxib , together with an effective amount of difluoromethylornithine.
|
